Get the Stockscreener App
3.90
0.65%
0.03
After Hours:
3.95
0.05
+1.28%
Atyr Pharma Inc stock is traded at $3.90, with a volume of 745.24K.
It is up +0.65% in the last 24 hours and up +0.13% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$3.87
Open:
$3.86
24h Volume:
745.24K
Relative Volume:
0.91
Market Cap:
$322.76M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.91%
1M Performance:
+0.13%
6M Performance:
+118.82%
1Y Performance:
+0.00%
1-Day Range:
$3.78
$3.975
1-Week Range:
$3.33
$3.99
52-Week Range:
$1.42
$4.225
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
3.90 | 322.76M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
Stocks of Atyr Pharma Inc (ATYR) are poised to climb above their peers - SETE News
Recent Insider Activity Suggests Potential Gains for Atyr Pharma Inc (ATYR) - Knox Daily
How to interpret Atyr Pharma Inc (ATYR)’s stock chart patterns - US Post News
aTyr Pharma CFO Broadfoot sells $4,740 in stock - MSN
Atyr Pharma's general counsel Nancy Denyes sells $3,398 in stock - MSN
Trading Day Review: Atyr Pharma Inc (ATYR) Loses Momentum, Closing at 3.57 - The Dwinnex
JPMorgan Chase & Co. Boosts Holdings in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Increases By 25.0% - MarketBeat
Head to Head Contrast: CERo Therapeutics (NASDAQ:CERO) versus Atyr PHARMA (NASDAQ:ATYR) - Defense World
Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation - Yahoo Finance
aTyr Pharma to Present Three Posters for Efzofitimod at the - GlobeNewswire
Revolutionary Lung Disease Treatment Shows Promise: Major Updates Coming at ATS 2025 - StockTitan
Cantor Fitzgerald Estimates Atyr PHARMA FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts Atyr PHARMA FY2025 Earnings - MarketBeat
Institutional investors are aTyr Pharma, Inc.'s (NASDAQ:ATYR) biggest bettors and were rewarded after last week's US$29m market cap gain - Simply Wall St
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Expands By 25.0% - MarketBeat
Cantor Fitzgerald Weighs in on Atyr PHARMA FY2024 Earnings - Defense World
Several Insiders Invested In aTyr Pharma Flagging Positive News - Yahoo Finance
aTyr Pharma: Interesting Drug, Difficult Target Market (ATYR) - Seeking Alpha
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Analysts at Cantor Fitzgerald - Defense World
This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
aTyr Pharma stock soars to 52-week high of $4.16 By Investing.com - Investing.com Canada
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Cantor Fitzgerald - MarketBeat
Head-To-Head Analysis: Atyr PHARMA (NASDAQ:ATYR) versus CG Oncology (NASDAQ:CGON) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Sees Significant Increase in Short Interest - MarketBeat
aTyr Pharma stock soars to 52-week high, hits $3.86 By Investing.com - Investing.com Canada
aTyr Pharma stock soars to 52-week high, hits $3.86 - Investing.com
SEC Form 424B5 filed by aTyr Pharma Inc. - Quantisnow
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57% - Yahoo Finance
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
aTyr Pharma to Present at JPMorgan Healthcare Conference: Spotlight on Revolutionary tRNA Platform - StockTitan
aTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlook - Investing.com
aTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlook By Investing.com - Investing.com Canada
aTyr Pharma expands board with new director appointment By Investing.com - Investing.com Canada
ATyr Pharma, Inc. Appoints Eric Benevich to Its Board of Directors - Marketscreener.com
aTyr Pharma expands board with new director appointment - Investing.com India
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors - The Manila Times
aTyr Pharma Strengthens Board with Neurocrine CCO Eric Benevich, Bolsters Commercial Leadership - StockTitan
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - The Manila Times
aTyr Pharma Announces Third Positive DSMB Review for - GlobeNewswire
aTyr Pharma's Efzofitimod Phase 3 Trial Clears Critical Safety Review for Pulmonary Sarcoidosis Treatment - StockTitan
Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Survey - Defense World
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis - The Manila Times
aTyr Pharma to Present Preclinical Research Demonstrating - GlobeNewswire
aTyr Pharma's Novel Fibrosis Treatment Shows Breakthrough Results in Preclinical Studies - StockTitan
Sarcoidosis Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharma, Novartis, Kinevant Sciences - Barchart
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Atyr Pharma Inc Stock (ATYR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
| SCHIMMEL PAUL | Director |
Jul 24 '24 |
Buy |
1.93 |
52,300 |
101,038 |
413,023 |
| SCHIMMEL PAUL | Director |
Jul 22 '24 |
Buy |
1.74 |
41,052 |
71,500 |
354,075 |
| SCHIMMEL PAUL | Director |
Jul 23 '24 |
Buy |
1.82 |
6,648 |
12,075 |
360,723 |
| DENYES NANCY | General Counsel |
Jun 05 '24 |
Buy |
1.86 |
5,000 |
9,276 |
22,267 |
| COUGHLIN TIMOTHY | Director |
May 30 '24 |
Buy |
1.75 |
50,000 |
87,500 |
56,000 |
| Broadfoot Jill Marie | Chief Financial Officer |
May 31 '24 |
Buy |
1.79 |
5,000 |
8,950 |
27,960 |
| Shukla Sanjay | President and CEO |
May 31 '24 |
Buy |
1.81 |
20,000 |
36,140 |
136,548 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):